吉西他滨联合替吉奥方案治疗晚期胆囊癌临床观察

Clinical observation of gemcitabine combined with tegafur in the treatment of advanced gall bladder cancer

目的评价吉西他滨联合替吉奥治疗晚期胆囊癌的近期疗效和毒副反应。方法对28例晚期胆囊癌患者采用吉西他滨联合替吉奥方案治疗,吉西他滨1000 mg/m2,第1、8天静脉给药;替吉奥60 mg/m2/d,分2次口服,第1~14天,3周为1周期,至少应用2周期,2个疗程后评价患者的疗效、临床受益反应、毒副反应等。结果入组28例均可评价疗效,治疗后完全缓解1例,部分缓解8例、稳定10例、进展9例,总有效率为32.1%,肿瘤控制率53.6%。无严重不良事件发生,无一例死亡,主要的不良反应为骨髓抑制、恶心呕吐、皮疹、肝功能损害。结论吉西他滨联合替吉奥治疗晚期胆囊癌近期疗效较好,毒性反应较轻,患者可以耐受。

Objective To evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and tegafur in the treatment of advanced gall bladder cancer. Methods Twenty-eight patients with advanced gall bladder cancer received gemcitabine and tegafur combination regimen( gemcitabine: 1000 mg / m2 though intravenous on day 1 and 8 plus tegafur 60 mg / m2/ d,twice daily during day 1 ~ 14). The regimen was repeated at least two cycles of three weeks each and the clinical response was recorded at two weeks after treatment. Results Of the 28 patients,the overall response rate was 32. 1%,and the clinical benefit response was 53. 6%,including 1 patient with complete remission and 8 patients with partial remission. The symptoms were stable in 10 patients and progressive in 10 patients. There was no severe complication or death observed. The most frequent treatment-related adverse event were hematological toxicity,nausea,vomiting,rash and hepatic function impairment. Conclusion Gemcitabine combined with tegafur in the treatment of patients with advanced gall bladder cancer has good short-term effect with minimal adverse reaction and can be tolerated by patients.